BMS-180194 has potent activity against CMV in vitro and in animal models of herpesvirus infections, as well as good oral bioavailability in a variety of animal species. This sequential, ascending-dose study is the first trial of BMS-180194 in man, and is designed to assess the pharmacokinetics, tolerance, and safety of single oral and intravenous doses of the drug.
Showing the most recent 10 out of 65 publications